lamivudine
lamivudine is listed in the FDA National Drug Code directory with 17 NDC codes, marketed under brand names including LAMIVUDINE, EPIVIR, lamivudine. Available dosage forms: tablet, film coated, powder, solution.
Drug details
- Generic Name
- lamivudine
- Brand Names
- LAMIVUDINE, EPIVIR, lamivudine
- Application Number
- ANDA091606
- Sponsor
- Apotex Corp.
- NDC Codes
- 17
- Dosage Forms
- TABLET, FILM COATED, POWDER, SOLUTION
- Routes
- ORAL
- Active Ingredients
- LAMIVUDINE
Indications and Usage
1 INDICATIONS AND USAGE Lamivudine tablets (HBV) are indicated for the treatment of chronic hepatitis B virus (HBV) infection associated with evidence of hepatitis B viral replication and active liver inflammation [see Clinical Studies ( 14.1 , 14.2 )]. The following points should be considered when initiating therapy with lamivudine tablets (HBV): • Due to high rates of resistance development in treated patients, initiation of treatment with lamivudine tablets (HBV) should only be considered when the use of an alternative antiviral agent with a higher genetic barrier to resistance is not available or appropriate. • Lamivudine tablets (HBV) have not been evaluated in patients co-infected with human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis delta virus. • Lamivudine tablets (HBV) have not been evaluated in liver transplant recipients or in patients with chronic hepatitis B virus infection with decompensated liver disease. Lamivudine tablets (HBV) are a nucleoside analogue reverse transcriptase inhibitor indicated for the treatment of chronic hepatitis B virus (HBV) infection associated with evidence of hepatitis B viral replication and active liver inflammation. ( 1 )